There is also evidence for the involvement of drug exporters such as ABCB1/MDR (176)1/PGP and ABCG2/BCRP in the development of TKI resistance in CML (112, 176–178). This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.